Lesson plan
Dimestrol
Dimestrol (brand names Depot-Cyren, Depot-Oestromon), also known as dianisylhexene, 4,4'-dimethoxy-α,α'-diethylstilbene, diethylstilbestrol dimethyl ether, and dimethoxydiethylstilbestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group which is related to diethylstilbestrol. It has been used clinically as a hormonal therapy in cases of delayed female puberty, hypogonadism, menopausal, and postmenopausal symptoms. It is known to induce the development of female secondary sexual characteristics in the case of female delayed puberty or hypogonadism. The drug has also been used as a growth promoter in livestock. DES is a known endocrine disrupting chemical. Molecularly, it is known to increase the risk of aneuploidy via interference with microtubule assembly. Prior to the 1950s, DES was widely prescribed to pregnant women to prevent miscarriage and preterm labor. A study released in the 1950s found that women who were exposed to DES were at increased risk for cervical and vaginal clear cell adenocarcinoma. Shortly after this finding, the FDA discouraged the prescription of DES to pregnant women. Children were also affected by the maternal use of DES during their gestation.…
Article summary
Dimestrol (brand names Depot-Cyren, Depot-Oestromon), also known as dianisylhexene, 4,4'-dimethoxy-α,α'-diethylstilbene, diethylstilbestrol dimethyl ether, and dimethoxydiethylstilbestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group which is related to diethylstilbestrol. It has been used clinically as a hormonal therapy in cases of delayed female puberty, hypogonadism, menopausal, and postmenopausal symptoms. It is known to induce the development of female secondary sexual characteristics in the case of female delayed puberty or hypogonadism. The drug has also been used as a growth promoter in livestock. DES is a known endocrine disrupting chemical. Molecularly, it is known to increase the risk of aneuploidy via interference with microtubule assembly. Prior to the 1950s, DES was widely prescribed to pregnant women to prevent miscarriage and preterm labor. A study released in the 1950s found that women who were exposed to DES were at increased risk for cervical and vaginal clear cell adenocarcinoma. Shortly after this finding, the FDA discouraged the prescription of DES to pregnant women. Children were also affected by the maternal use of DES during their gestation.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.